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An economic evaluation has been performed, analyzing
direct medical costs for the treatment of perennial allergic
rhinitis (PAR) with budesonide aqueous nasal spray and
fluticasone propionate nasal spray in Canada.
BACKGROUND: In this study, 314 patients, with at
least a 1-year history of PAR, were randomized into a
double-blind, parallel group study of 6 weeks duration.
The treatments were budesonide 256 g, fluticasone pro-
pionate 200 g, or placebo. Budesonide was significantly
more effective than fluticasone in reducing “blocked
nose.” Both active treatments produced significantly lower
mean scores for overall nasal symptoms compared with
placebo, and both were well tolerated. 
METHOD: A cost-minimization analysis, utilizing the clin-
ical trial data, was performed of the total costs of 1) budes-
onide-based and 2) fluticasone-based treatment strategies,
including the relative importance of the drug cost in both
strategies. 
RESULTS: In Canada, the average treatment cost per pa-
tient over 12 months in the budesonide group was CAN$
389.85 which was 23.3% lower than in the fluticasone
group, CAN$ 508.06, due to lower drug acquisition
costs. Drug costs represented between 24.6% and 42.1%
of total treatment costs for the budesonide and the fluti-
casone group, respectively. 
CONCLUSION: Budesonide aqueous nasal spray is a
cost-effective strategy in the treatment of perennial aller-
gic rhinitis.
ECONOMIC AND OUTCOMES ISSUES OF 
INFECTIOUS DISEASE
PID1
COST-EFFECTIVENESS ANALYSIS OF 
RECOMBINANT HUMAN ERYTHROPOIETIN 
VERSUS TRANSFUSION IN HIV PATIENTS 
TREATED WITH ZIDOVUDINE
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OBJECTIVE: The purpose of this study was to determine
the cost-effectiveness of erythropoietin against transfu-
sion in HIV patients treated with zidovudine from the so-
cietal perspective. 
METHOD: Cost-effectiveness was measured based on
probability of response to dose. The cost of drug with
and without the patient drug expenditure cap under the
Manufacturers’ Patient Assistance Program was consid-
ered. Measured were incremental cost per unit of blood
spared and incremental cost per QALY. Sensitivity analy-
sis was performed on all variables in the base case. 
RESULTS: Without the drug expenditure cap, the incre-
mental cost per unit of blood spared was $577.93
($160.34 with the cap). The incremental cost per QALY
without the cap was $118,620.13 and $32,909.71 with
the cap. The cost per unit of blood with the cap was 28%
below the cost of a unit of blood (PRBC). The break-even
cost of the drug was 77% below the current cost. A plot
of the cap against the cost per unit of blood spared
yielded a straight line. The cost per unit of blood spared
became zero at $4363.25 and became equal to the cost of
a unit of blood at $10,145. 
CONCLUSION: With the cost cap, erythropoietin can
be justified by incremental cost per QALY and on its
blood sparing and cost saving effects. The drug is most
cost-effective when it obviates the need for transfusion
entirely while it cannot be justified in patients who would
otherwise require 3 units of blood or less per month.
Variations in the cost of transfused blood units impact
cost-effectiveness but remain within acceptable limits for
typically cited values.
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INCREASED COST OF MANAGING AIDS IN THE 
LAST YEAR OF LIFE
O’Brien JA, Pierce D, Jackson-Kelley H, Cutter T, Caro JJ
Caro Research, Concord, MA, USA
It is possible with highly active antiretroviral therapy
(HAART) to retard progression from the HIV positive
state to AIDS. In developing an economic model of
HAART, annual costs associated with managing HIV
positive or symptomatic patients, and those with AIDS
were estimated. This presentation will focus on one as-
pect of this complex cost profile: the difference in the
management costs in a year where the AIDS patient sur-
vives versus the last year of life. 
OBJECTIVE: To estimate the difference in cost of AIDS
management between the last year of life and preceding
years. 
METHODS: Annual cost estimates include acute and sub-
acute inpatient care, outpatient care (excluding medica-
tions), emergency room, home care, hospice, counseling
and social services. Patient level data from the Massachu-
setts all payer discharge database allowed examination of
inpatient admissions for a cohort (n  340) of AIDS pa-
tients over 3 years (1994–1996). Patterns of inpatient care
for those discharged alive versus those who died in 1996
who also had admissions in 1994 and 1995 were con-
trasted. Additional 1996 data from 49,000 AIDS dis-
charges from six states were used to estimate inpatient
costs. These sources were supplemented by fee schedules,
other agency data and the literature. Costs are reported in
1998 US dollars, adjusted for medical inflation and cost-
to-charge ratios. 
RESULTS: The mean annual cost of acute inpatient care
is 36% higher in the last year of life ($31,302) than in
preceding years ($27,520). Inclusion of other resource
use increases the difference in management costs almost
three-fold ($18,289 versus $6,540). 
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CONCLUSION: There is a substantial increase in the
management costs of AIDS in the last year of life.
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ECONOMIC EVALUATION OF SYSTEMIC 
TREATMENTS FOR CMV RETINITIS IN PERSONS 
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OBJECTIVE: To determine the cost impact of four sys-
temic regimens for the treatment of newly diagnosed cy-
tomegalovirus (CMV) retinitis in persons with AIDS. 
METHODS: An incidence-based simulation model was
developed to evaluate the economic implications of treat-
ing CMV retinitis from a government payer perspective.
The model randomly assigned patients to one of four sys-
temic treatment regimens for induction and maintenance
therapies: 1) ganciclovir IV/IV; 2) ganciclovir IV/PO; 3)
foscarnet IV/IV; and 4) cidofovir IV/IV. Following a sec-
ond relapse patients were randomly assigned an alterna-
tive therapy in order to assess the impact of various fail-
ure treatment strategies. Efficacy and safety data were
extracted from a systematic review of available literature
and publicly available sources. Resource use and cost
data were obtained from a large, AIDS treatment facility
in Switzerland. The primary outcome measures were time
to first and subsequent progression, duration of mainte-
nance treatment, and associated direct medical expendi-
tures (1998 Swiss francs). Nonmedical costs and quality
of life benefits were not considered. 
RESULTS: The median time to first progression was
greatest for cidofovir followed by foscarnet, ganciclovir
IV, and ganciclovir PO. The average 1-year costs in the
base case were lowest in patients initially randomized to
cidofovir (87,867 CHF) followed by randomization to
ganciclovir IV/PO (110,410 CHF), ganciclovir IV/IV
(117,406 CHF), and foscarnet IV/IV (120,662 CHF).
Sensitivity analyses of costs, effectiveness, and adverse
event rates resulted in changes in the cost estimates, how-
ever the order remained unchanged. 
CONCLUSIONS: Of the four treatment regimens stud-
ied, beginning treatment with systemic cidofovir is most
effective and least costly over a 1-year period.
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A RETROSPECTIVE DATABASE STUDY OF AIDS 
INITIAL TREATMENT REGIMENS, SWITCHING 
PATTERNS, AND PATIENT ADHERENCE
Hutchison S, Beno C
PCS Health Systems, Inc., Outcomes Research Department, 
Scottsdale, AZ, USA
OBJECTIVES: AIDS treatment specialists advocate ag-
gressive (triple drug therapy) treatment of HIV/AIDS, but
limited research suggests that this position is not widely
held. Database studies are being used increasingly to pro-
vide information about patient behavior (e.g., identifica-
tion of treatment regimens and adherence with treatment
regimens). 
METHODS: A retrospective database study was con-
ducted to identify initial treatment regimens prescribed
for patients, changes in treatment regimens over time,
and patient adherence to their treatment regimens. 
RESULTS: Two patient cohorts were identified: one initi-
ating therapy after triple drug therapy was introduced and
before it was advocated as the treatment of choice; and
one initiating therapy after triple drug therapy was advo-
cated by HHS and the AMA. AIDS drugs prescriptions
filled for a 12-month period following initiation of therapy
were extracted from the database for each patient cohort. 
RESULTS: Findings indicate that 1) triple drug therapy is
not widely prescribed as an initiation therapy, 2) after
initiating therapy many patients must switch or augment
their treatment regimens, and 3) after 12 months of ther-
apy the triple drug regimen is still not widely prescribed. 
CONCLUSIONS: The results of this study provide further
evidence of the utility of retrospective database studies to
provide healthcare providers with cost-effective healthcare
delivery information.
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DEVELOPMENT AND INITIAL ASSESSMENT OF 
THE PATIENT MEDICATION ADHERENCE 
QUESTIONNAIRE-7 FOR USE IN 
INTERNATIONAL HIV STUDIES
Metcalf M1, Jhingran P1, Tolson J1, Arpinelli F2, Pham S1
1Glaxo Wellcome Inc., Research Triangle Park, NC, USA; 
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Data support the link between adherence to HIV treatment
and detectability of HIV RNA (a predictor of disease pro-
gression), making adherence a vital issue in HIV therapy. 
OBJECTIVE: To develop and assess a questionnaire to
measure adherence to HIV treatment. 
METHODS: Items from two existing measures, the Pa-
tient Medication Adherence Questionnaire (PMAQ) and
the Treatment Review and Satisfaction Questionnaire
(TRaSQ), were tested and revised using feedback from fo-
cus groups and in-depth interviews with 28 US and 29 Ital-
ian HIV-infected patients. This assessment highlighted is-
sues surrounding adherence, including patient beliefs,
knowledge and attitudes, lifestyle changes, medication
characteristics, regimen complexity, side effects, patient-
provider relationships, and patient recall. The subsequent
instrument, the PMAQ7, contains Likert-type items ad-
dressing these issues, and a behavioral assessment of ad-
herence over the past 7 days. 
RESULTS: Patients indicated that the PMAQ7 addressed
issues that were important to HIV patients, including side
effects and convenience of regimens. They added that an
issue’s importance could vary with the length of time that
a patient has been on HIV treatment. In addition, cultural
